New drug shows promise in slowing advanced breast cancer with ESR1 mutation
Disease control
Completed
This study tested a new drug, lasofoxifene, against the standard treatment fulvestrant in 100 women with advanced ER+/HER2- breast cancer that has a specific mutation in the ESR1 gene. The goal was to see if lasofoxifene could delay cancer growth longer than fulvestrant. Particip…
Phase: PHASE2 • Sponsor: Sermonix Pharmaceuticals Inc. • Aim: Disease control
Last updated May 17, 2026 15:09 UTC